Decrease of Fibulin-3 in Hepatocellular Carcinoma Indicates Poor Prognosis

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Luo, Rongzhen ^a   Zhang, Meifang ^a   Liu, Lili ^a   Lu, Shixun ^a   Zhang, Chris Zhiyi ^a   Yun, Jingping ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; FIBULIN; FIBULIN 3; HEPATITIS B SURFACE ANTIGEN; MESSENGER RNA; SMALL INTERFERING RNA; TUMOR MARKER; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CELL INVASION; CELL VIABILITY; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; FEMALE; GENE SILENCING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CANCER; OVERALL SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEIVER OPERATING CHARACTERISTIC; RECURRENCE FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SURVIVAL TIME; TUMOR DIFFERENTIATION; TUMOR INVASION; WESTERN BLOTTING;

ADOLESCENT; ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; EXTRACELLULAR MATRIX PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; PROGNOSIS; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 84881017202     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070511     Document Type: Article

References (35)

1. Jemal A, Bray F, (2011) Center MM, Ferlay J, Ward E, et al (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Bosch FX, Ribes J, Diaz M, Cleries R, (2004) Primary liver cancer: worldwide incidence and trends. Gastroenterology 127: S5-S16.
3. Erichsen R, Jepsen P, Jacobsen J, Norgaard M, Vilstrup H, et al. (2008) Time trends in incidence and prognosis of primary liver cancer and liver metastases of unknown origin in a Danish region, 1985-2004. Eur J Gastroenterol Hepatol 20: 104-110.
4. Marquardt JU, Galle PR, Teufel A, (2012) Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): an emerging field for advanced technologies. J Hepatol 56: 267-275.
5. Breuhahn K, Gores G, Schirmacher P, (2011) Strategies for hepatocellular carcinoma therapy and diagnostics: lessons learned from high throughput and profiling approaches. Hepatology 53: 2112-2121.
6. Wong DK, Huang FY, Lai CL, Poon RT, Seto WK, et al. (2011) Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. Hepatology 54: 829-836.
7. Riordan JD, Keng VW, Tschida BR, Scheetz TE, Bell JB, et al. (2013) Identification of rtl1, a retrotransposon-derived imprinted gene, as a novel driver of hepatocarcinogenesis. PLoS Genet 9: e1003441.
8. Timpl R, Sasaki T, Kostka G, Chu ML, (2003) Fibulins: a versatile family of extracellular matrix proteins. Nat Rev Mol Cell Biol 4: 479-489.
9. de Vega S, Iwamoto T, Yamada Y, (2009) Fibulins: multiple roles in matrix structures and tissue functions. Cell Mol Life Sci 66: 1890-1902.
10. Argraves WS, Greene LM, Cooley MA, Gallagher WM, (2003) Fibulins: physiological and disease perspectives. EMBO Rep 4: 1127-1131.
11. Ehlermann J, Weber S, Pfisterer P, Schorle H, (2003) Cloning, expression and characterization of the murine Efemp1, a gene mutated in Doyne-Honeycomb retinal dystrophy. Gene Expr Patterns 3: 441-447.
12. Narendran N, Guymer RH, Cain M, Baird PN, (2005) Analysis of the EFEMP1 gene in individuals and families with early onset drusen. Eye (Lond) 19: 11-15.
13. Blackburn J, Tarttelin EE, Gregory-Evans CY, Moosajee M, Gregory-Evans K, (2003) Transcriptional regulation and expression of the dominant drusen gene FBLN3 (EFEMP1) in mammalian retina. Invest Ophthalmol Vis Sci 44: 4613-4621.
14. Pass HI, Levin SM, Harbut MR, Melamed J, Chiriboga L, et al. (2012) Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med 367: 1417-1427.
15. Seeliger H, Camaj P, Ischenko I, Kleespies A, De Toni EN, et al. (2009) EFEMP1 expression promotes in vivo tumor growth in human pancreatic adenocarcinoma. Mol Cancer Res 7: 189-198.
16. En-lin S, Sheng-guo C, Hua-qiao W, (2010) The expression of EFEMP1 in cervical carcinoma and its relationship with prognosis. Gynecol Oncol 117: 417-422.
17. Hu B, Thirtamara-Rajamani KK, Sim H, Viapiano MS, (2009) Fibulin-3 is uniquely upregulated in malignant gliomas and promotes tumor cell motility and invasion. Mol Cancer Res 7: 1756-1770.
18. Tong JD, Jiao NL, Wang YX, Zhang YW, Han F, (2011) Downregulation of fibulin-3 gene by promoter methylation in colorectal cancer predicts adverse prognosis. Neoplasma 58: 441-448.
19. Yue W, Dacic S, Sun Q, Landreneau R, Guo M, et al. (2007) Frequent inactivation of RAMP2, EFEMP1 and Dutt1 in lung cancer by promoter hypermethylation. Clin Cancer Res 13: 4336-4344.
20. Sadr-Nabavi A, Ramser J, Volkmann J, Naehrig J, Wiesmann F, et al. (2009) Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker. Int J Cancer 124: 1727-1735.
21. Kim YJ, Yoon HY, Kim SK, Kim YW, Kim EJ, et al. (2011) EFEMP1 as a novel DNA methylation marker for prostate cancer: array-based DNA methylation and expression profiling. Clin Cancer Res 17: 4523-4530.
22. Hwang CF, Chien CY, Huang SC, Yin YF, Huang CC, et al. (2010) Fibulin-3 is associated with tumour progression and a poor prognosis in nasopharyngeal carcinomas and inhibits cell migration and invasion via suppressed AKT activity. J Pathol 222: 367-379.
23. Nomoto S, Kanda M, Okamura Y, Nishikawa Y, Qiyong L, et al. (2010) Epidermal growth factor-containing fibulin-like extracellular matrix protein 1, EFEMP1, a novel tumor-suppressor gene detected in hepatocellular carcinoma using double combination array analysis. Ann Surg Oncol 17: 923-932.
24. Zhang CZ, Liu L, Cai M, Pan Y, Fu J, et al. (2012) Low SIRT3 expression correlates with poor differentiation and unfavorable prognosis in primary hepatocellular carcinoma. PLoS One 7: e51703.
25. Shen Q, Fan J, Yang XR, Tan Y, Zhao W, et al. (2012) Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol 13: 817-826.
26. Liu L, Zhang CZ, Cai M, Fu J, Chen GG, et al. (2012) Downregulation of polo-like kinase 4 in hepatocellular carcinoma associates with poor prognosis. PLoS One 7: e41293.
27. Song EL, Hou YP, Yu SP, Chen SG, Huang JT, et al. (2011) EFEMP1 expression promotes angiogenesis and accelerates the growth of cervical cancer in vivo. Gynecol Oncol 121: 174-180.
28. Camaj P, Seeliger H, Ischenko I, Krebs S, Blum H, et al. (2009) EFEMP1 binds the EGF receptor and activates MAPK and Akt pathways in pancreatic carcinoma cells. Biol Chem 390: 1293-1302.
29. Hu B, Nandhu MS, Sim H, Agudelo-Garcia PA, Saldivar JC, et al. (2012) Fibulin-3 promotes glioma growth and resistance through a novel paracrine regulation of Notch signaling. Cancer Res 72: 3873-3885.
30. Hu Y, Pioli PD, Siegel E, Zhang Q, Nelson J, et al. (2011) EFEMP1 suppresses malignant glioma growth and exerts its action within the tumor extracellular compartment. Mol Cancer 10: 123.
31. Albig AR, Neil JR, Schiemann WP, (2006) Fibulins 3 and 5 antagonize tumor angiogenesis in vivo. Cancer Res 66: 2621-2629.
32. Kim EJ, Lee SY, Woo MK, Choi SI, Kim TR, et al. (2012) Fibulin-3 promoter methylation alters the invasive behavior of non-small cell lung cancer cell lines via MMP-7 and MMP-2 regulation. Int J Oncol 40: 402-408.
33. Diersch S, Wenzel P, Szameitat M, Eser P, Paul MC, et al. (2013) Efemp1 and p27(Kip1) modulate responsiveness of pancreatic cancer cells towards a dual PI3K/mTOR inhibitor in preclinical models. Oncotarget 4: 277-288.
34. Sercu S, Lambeir AM, Steenackers E, El Ghalbzouri A, Geentjens K, et al. (2009) ECM1 interacts with fibulin-3 and the beta 3 chain of laminin 332 through its serum albumin subdomain-like 2 domain. Matrix Biol 28: 160-169.
35. Klenotic PA, Munier FL, Marmorstein LY, Anand-Apte B, (2004) Tissue inhibitor of metalloproteinases-3 (TIMP-3) is a binding partner of epithelial growth factor-containing fibulin-like extracellular matrix protein 1 (EFEMP1). Implications for macular degenerations. J Biol Chem 279: 30469-30473.